| Some puzzling pharmacological effects of monoamine oxidase inhibitors. J Knoll, K Magyar Advances Biochem Psychopharmacol 5, 393, 1972 | 1128 | 1972 |
| Improvement of life expectancy due to L-deprenyl addition to Madopar treatment in Parkinson's disease: a long-term study W Birkmayer, J Knoll, P Riederer, V Hars, J Marton J Neural Transm 64, 113-127, 1985 | 588* | 1985 |
| H., Hars V., and Martin J.(1985) Increased life expectancy resulting from addition of L-deprenyl to Mapodar treatment in Parkinson’s disease. A long-term study. J W Birkmayer, J Knoll, P Riederer, MB Youdim NeirraI 7runsrn 64, 0 | 576* | |
| Increased life expectancy resulting from addition of L-deprenyl to Madopar® treatment in Parkinson's disease: a longterm study W Birkmayer, J Knoll, P Riederer, MBH Youdim, V Hars, J Marton Journal of neural transmission 64 (2), 113-127, 1985 | 574 | 1985 |
| Archs int J Knoll, ES Vizi, Z Escseri Pharmacodyn. Ther 133, 310, 1961 | 331* | 1961 |
| The striatal dopamine dependency of life span in male rats. Longevity study with (−) deprenyl J Knoll Mechanisms of ageing and development 46 (1-3), 237-262, 1988 | 293 | 1988 |
| The inhibitory effect of adenosine and related nucleotides on the release of acetylcholine ES Vizi, J Knoll Neuroscience 1 (5), 391-398, 1976 | 279 | 1976 |
| Evidence that acetylcholine released by gastrin and related polypeptides contributes to their effect on gastrointestinal motility SE Vizi, G Bertaccini, M Impicciatore, J Knoll Gastroenterology 64 (2), 268-277, 1973 | 276 | 1973 |
| The possible mechanisms of action of (-) deprenyl in Parkinson's disease J Knoll Journal of Neural Transmission 43, 177-198, 1978 | 242 | 1978 |
| Deprenyl (selegiline): the history of its development and pharmacological action J Knoll Acta Neurologica Scandinavica 68, 57-80, 1983 | 238 | 1983 |
| (−)-Deprenyl leads to prolongation of l-dopa efficacy in Parkinson’s disease W Birkmayer, J Knoll, P Riederer, MBH Youdim Monoamine Oxidase and its Selective Inhibitors 19, 170-176, 1983 | 198 | 1983 |
| Monoamine oxidase and its inhibition J Knoll, GEW Wolstenholme Ciba Foundation Symposium 39, 135-155, 1976 | 174* | 1976 |
| Striatal dopamine, sexual activity and lifespan. Longevity of rats treated with (-) deprenyl J Knoll, J Dallo, TT Yen Life sciences 45 (6), 525-531, 1989 | 162 | 1989 |
| The pharmacology of selegiline ((−) deprenyl). New aspects J Knoll Acta Neurologica Scandinavica 80, 83-91, 1989 | 156 | 1989 |
| Marker-assisted selection in sorghum G Ejeta, JE Knoll Genomics-assisted crop improvement: Vol 2: Genomics applications in crops …, 2007 | 133 | 2007 |
| Novel (-) deprenyl-derived selective inhibitors of B-type monoamine oxidase. The relation of structure to their action J Knoll, Z Ecsery, K Magyar, S E Biochem Pharmacol 27, 1739-1747, 1978 | 129 | 1978 |
| R-(-)-deprenyl (Selegiline, Movergan) facilitates the activity of the nigrostriatal dopaminergic neuron. J Knoll Journal of neural transmission. Supplementum 25, 45-66, 1987 | 127 | 1987 |
| The effects of sympathetic nerve stimulation and guanethidine on parasympathetic neuroeffector transmission; the inhibition of acetylcholine release ES Vizi, J Knoll Journal of Pharmacy and Pharmacology 23 (12), 918-925, 1971 | 126 | 1971 |
| The effect of artificial selection on phenotypic plasticity in maize JL Gage, D Jarquin, C Romay, A Lorenz, ES Buckler, S Kaeppler, ... Nature communications 8 (1), 1348, 2017 | 124 | 2017 |
| QTL analysis of early-season cold tolerance in sorghum J Knoll, N Gunaratna, G Ejeta Theoretical and Applied Genetics 116, 577-587, 2008 | 123 | 2008 |
Ildikó MiklyaSemmelweis University, Department of Pharmacology and PharmacotherapyVerified email at med.semmelweis-univ.hu
